Trial ID or NCT#

NCT03445533

Status

not recruiting iconNOT RECRUITING

Purpose

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

Official Title

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sunil Arani Reddy
Sunil Arani Reddy
Medical oncologist, Cutaneous oncology specialist
Clinical Assistant Professor, Medicine - Oncology
Dana Lin, MD
Dana Lin, MD
General surgeon, Thyroid and parathyroid surgeon, Melanoma surgeon, Surgical oncologist, Endocrine surgeon, Dermatologic surgeon
Clinical Assistant Professor, Surgery - General Surgery

Contact us to find out if this trial is right for you.

CONTACT

Phuong Pham
650-725-9810